Chemours Co

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

CC$13.48+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Interim Consolidated Statements of Operations (Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Net sales	$1,540	$1,495	$4,512	$4,478
Cost of goods sold	1,309	1,262	3,783	3,732
Gross profit	231	233	729	746
Selling, general, and administrative expense (1)	(25)	122	591	669
Research and development expense	24	26	77	81
Restructuring, asset-related, and other charges	3	4	19	55
Total other operating expenses	2	152	687	805
Equity in earnings of affiliates	11	9	28	27
Interest expense, net	(69)	(68)	(206)	(201)
Loss on extinguishment of debt	—	—	(11)	—
Other income, net	51	16	347	23
Income before income taxes	222	38	200	(210)
Provision for (benefit from) income taxes	26	(8)	307	128
Net income (loss)	196	46	(107)	(338)
Less: Net income attributable to non-controlling interests	—	—	—	1
Net income (loss) attributable to Chemours	$196	$46	$(107)	$(339)
Per share data
Basic earnings (loss) per share of common stock	$1.29	$0.31	$(0.71)	$(2.26)
Diluted earnings (loss) per share of common stock	1.29	0.31	(0.71)	(2.26)

(1)

Selling, general and administrative ("SG&A") expense for the three and nine months ended September 30, 2026 includes $150 received by the Company related to the PFAS Insurance MOU. See "Note 17 - Commitments and Contingent Liabilities"for further details.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.